- Companies
- TME Pharma
TME Pharma Valuation Multiples
TME Pharma is valued at $11M as of November 2026. In the last fiscal year, TME Pharma EBITDA was ($3M).
TME Pharma Overview
About TME Pharma
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Founded
2015
HQ
Employees
13
Website
Sectors
Financials (Last FY)
EV
$13M
Valuation Multiples
Start free trialTME Pharma Financials
TME Pharma reported last fiscal year revenue of - and negative EBITDA of ($3M).
In the same fiscal year, TME Pharma generated ($3M) in EBITDA losses and had net loss of ($4M).
Revenue (LTM)
TME Pharma P&L
In the most recent fiscal year, TME Pharma reported revenue of - and EBITDA of ($3M).
TME Pharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
TME Pharma Stock Performance
TME Pharma has current market cap of $11M, and enterprise value of $13M.
Market Cap Evolution
TME Pharma's stock price is $0.12.
TME Pharma share price decreased by 15.9% in the last 30 days, and increased by 50.6% in the last year.
TME Pharma has an EPS (earnings per share) of $-0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $11M | -1.0% | -15.9% | -26.8% | 50.6% | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTME Pharma Valuation Multiples
TME Pharma trades at (4.0x) EV/EBITDA.
EV / Revenue (LTM)
TME Pharma Financial Valuation Multiples
As of November 19, 2026, TME Pharma has market cap of $11M and EV of $13M.
TME Pharma has a P/E ratio of (3.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TME Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


TME Pharma Margins & Growth Rates
TME Pharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
TME Pharma Operational KPIs
TME Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
TME Pharma Competitors
TME Pharma competitors include Neuroscientific, Advicenne, Aspire Biopharma Holdings, Anebulo Pharmaceuticals, Vidac Pharma, IRLAB Therapeutics, Opthea, Imugene, Patrys and Medicenna Therapeutics.
Most TME Pharma public comparables operate across Biopharmaceuticals and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | - | - | |||
| $7M | ($9M) | 5.0x | 4.7x | (3.6x) | (8.5x) | |||
| $6K | ($16M) | 2473.8x | - | (1.0x) | - | |||
| - | ($8M) | - | - | (0.3x) | - | |||
| - | ($3M) | - | - | (4.6x) | - | |||
| $6M | ($8M) | 1.8x | 1.6x | (1.2x) | (2.5x) | |||
| $1K | ($10M) | - | - | - | - | |||
| - | ($68M) | - | - | (0.2x) | (0.4x) | |||
This data is available for Pro users. Sign up to see all TME Pharma competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TME Pharma
| When was TME Pharma founded? | TME Pharma was founded in 2015. |
| Where is TME Pharma headquartered? | TME Pharma is headquartered in Germany. |
| How many employees does TME Pharma have? | As of today, TME Pharma has over 13 employees. |
| Who is the CEO of TME Pharma? | TME Pharma's CEO is Diede Mink van den Ouden. |
| Is TME Pharma publicly listed? | Yes, TME Pharma is a public company listed on Euronext Paris. |
| What is the stock symbol of TME Pharma? | TME Pharma trades under ALTME ticker. |
| When did TME Pharma go public? | TME Pharma went public in 2016. |
| Who are competitors of TME Pharma? | TME Pharma main competitors include Neuroscientific, Advicenne, Aspire Biopharma Holdings, Anebulo Pharmaceuticals, Vidac Pharma, IRLAB Therapeutics, Opthea, Imugene, Patrys, Medicenna Therapeutics. |
| What is the current market cap of TME Pharma? | TME Pharma's current market cap is $11M. |
| Is TME Pharma profitable? | No, TME Pharma is not profitable. |
| How many companies TME Pharma has acquired to date? | TME Pharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies TME Pharma has invested to date? | TME Pharma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to TME Pharma
Lists including TME Pharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




